Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05694832 · ClinicalTrials.gov registry record · Early Phase 1
Expressive Writing in GVHD
A Early Phase 1 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT05694832 is a Early Phase 1 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 3 participants.
The verdict
NCT05694832, a Early Phase 1 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Graft-versus-host-disease (GVHD) is a disease phenomenon that occurs when immune cells of the donor recognize and attack healthy tissue within the transplant recipient, or host. It is ultimately the result of the same immunological mechanisms that provide benefit to patients receiving hematopoietic stem cell transplantation (HSCT). In patients with hematologic malignancies, HSCT can be therapeutic, as donor T cells recognize and mount a response against cancerous cells. HSCT is also used in the setting of certain immunodeficiencies and inborn errors of metabolism for which therapeutic benefit is found in immunologic repletion. To our knowledge, support groups have yet to be investigated in academic literature as a nonpharmacologic, therapeutic intervention for cutaneous GVHD patients to improve their distress, systemic disease, and quality of life. Given the dearth of research on nonpharmacologic therapies for cutaneous GVHD that address quality of life impairments, we seek to characterize the effect of an expressive writing and peer helping intervention contextualized within the framework of a support group. The primary goal of this study is to provide preliminary efficacy data of expressive writing as an intervention in patients with cutaneous GVHD to trial.
Interventions
- BEHAVIORAL Expressive Writing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-01-21 |
| Est. Completion | 2024-05-24 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05694832
The ClinicalTrials.gov registry entry for NCT05694832 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Expressive Writing is the first listed.
NCT05694832 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05694832 about?
NCT05694832 is a clinical study titled "Expressive Writing in GVHD". Graft-versus-host-disease (GVHD) is a disease phenomenon that occurs when immune cells of the donor recognize and attack healthy tissue within the transplant recipient, or host. It is ultimately the result of the same immunological mechanisms that provide benefit to patients receiving hematopoietic ...
What is the current status of trial NCT05694832?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2023-01-21. Estimated completion is 2024-05-24.
What interventions are being tested in trial NCT05694832?
The interventions under investigation include: Expressive Writing (BEHAVIORAL).
Who is sponsoring clinical trial NCT05694832?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.